Allogeneic transplant for older AML patients - who, when and how British Society of Haematology

Allogeneic transplant for older AML patients - who, when and how British Society of Haematology

VJHemOnc

3 years
684 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK discusses when a transplant is the most suitable option in elderly acute myeloid leukemia (AML) patients and what alternatives are open to these patients. Prof Craddock first explains how one can determine the quality of remission using minimal residual disease (MRD) testing, cytogenetic and molecular analysis. He then further explains how patients with a predicted risk of relapse higher than 40% will benefit from an allograft, as well as how co-morbidities scores should be considered when determining whether an allograft is suitable. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland
Up Next Autoplay